CI
DMAC icon

Corient IA’s DiaMedica Therapeutics DMAC Stock Holding History

Corient IA’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Buy
+60,000
New +$475K 0.38% 90
2025
Q4 		– Sell
-132,500
Closed -$910K – 214
2025
Q3 		$910K Buy
+132,500
New +$719K 0.68% 33

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Corient IA's DMAC Position: Q1 2026 in Review

Corient IA opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 60,000 shares worth $406K. The stake represents 0.38% of the portfolio and ranks #90 among its holdings. This is a return to the name: Corient IA previously reported a position in DMAC as recently as Q3 2025.

Corient IA first reported a position in DMAC in Q3 2025 and has held it in 2 quarters since. The position peaked at $910K in Q3 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Corient IA held 60,000 shares of DiaMedica Therapeutics worth $406K as of Q1 2026.
  • DiaMedica Therapeutics was a new Corient IA position in Q1 2026.
  • DiaMedica Therapeutics made up 0.38% of Corient IA's portfolio in Q1 2026, its #90 holding.
  • Corient IA first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Corient IA's DiaMedica Therapeutics position peaked at $910K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Corient IA's 13F filing for Q1 2026, filed 14 May 2026.